About Perfuse Therapeutics
Perfuse Therapeutics is a company based in San Francisco (United States) founded in 2018 by Sevgi Gurkan was acquired by Bayer in May 2026. Perfuse Therapeutics offers products and services including Endothelin Antagonist. Perfuse Therapeutics operates in a competitive market with competitors including Bausch & Lomb, Dopavision, Appasamy Associates, Katalyst Surgical and Lamellar, among others.
- Headquarter San Francisco, United States
- Founders Sevgi Gurkan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Perfuse Therapeutics, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Perfuse Therapeutics
Perfuse Therapeutics offers a comprehensive portfolio of products and services, including Endothelin Antagonist.
Improves blood flow to retina to treat glaucoma and diabetic retinopathy.
People of Perfuse Therapeutics
Unlock access to complete
Product Management Team
4 people
Principal Team
2 people
Analytical Team
1 people
Leadership Team
1 people
Unlock access to complete
Funding Insights of Perfuse Therapeutics
Investors in Perfuse Therapeutics
Perfuse Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer and Access Industries.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and holding company controlled by Len Blavatnik
|
Locked | Locked | Locked | |
|
Life science solutions for healthcare and agriculture are delivered.
|
Locked | Locked | Locked |
Investor details for Perfuse Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Perfuse Therapeutics
Investment portfolio details for Perfuse Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Perfuse Therapeutics
Detailed financials for Perfuse Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Perfuse Therapeutics Comparisons
Peer comparison for Perfuse Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Perfuse Therapeutics
Perfuse Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bausch & Lomb, Dopavision, Appasamy Associates, Katalyst Surgical and Lamellar, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ophthalmic pharmaceuticals and instruments are developed for eye care.
|
|
| Locked | Locked | Locked |
Digital therapeutics for myopia are developed via retinal light stimulation.
|
|
| Locked | Locked | Locked |
Ophthalmic instruments and pharmaceutical products are developed for eye care.
|
|
| Locked | Locked | Locked |
Titanium ophthalmic surgical instruments are manufactured and repaired.
|
|
| Locked | Locked | Locked |
Develops patented medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies
|
|
| Locked | Locked | Locked |
Precision instruments for eye surgery are designed and manufactured.
|
Detailed competitors of Perfuse Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Perfuse Therapeutics
Complete news archive for Perfuse Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perfuse Therapeutics
Perfuse Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Perfuse Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Sevgi Gurkan is the current CEO of Perfuse Therapeutics. They have also founded this company.
Perfuse Therapeutics was founded in 2018 in San Francisco, United States, within the biotechnology sector. Focus is placed on developing treatments for eye disorders, including glaucoma and retinal diseases. A proprietary technology is employed to enhance retinal perfusion, targeting improved outcomes in these conditions. Operations center on therapeutic innovation for ocular health applications.
Perfuse Therapeutics's top competitors include Bausch & Lomb, Appasamy Associates and Katalyst Surgical.
Perfuse Therapeutics offers Endothelin Antagonist.
Perfuse Therapeutics has 2 investors. Key investors include Bayer, and Access Industries.